Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
CASE REPORTS
Anti-interleukin-6 Receptor Antibody (Tocilizumab) Treatment of Multicentric Castleman's Disease
Masashi MatsuyamaTakeshi SuzukiHiroto TsuboiSatoshi ItoMizuko MamuraDaisuke GotoIsao MatsumotoAkito TsutsumiTakayuki Sumida
Author information
JOURNALS OPEN ACCESS

2007 Volume 46 Issue 11 Pages 771-774

Details
Abstract

We report three cases of multicentric Castleman's disease (MCD) successfully treated with anti-interleukin-6 receptor antibody (tocilizumab). Tocilizumab was administered intravenously at a dose of 8 mg/kg every 2 weeks. In each case, tocilizumab alleviated symptoms, including generalized fatigue, pyrexia, and alleviated biochemical abnormalities, including anemia, hypoalbuminemia, hypergammaglobulinemia, and increased C-reactive protein (CRP). Side effects included hypercholesterolemia, acute pyelonephritis, mild inflammation of the parotid glands, and upper respiratory system inflammation. Other severe side effects were not observed. These results indicate that tocilizumab is effective for the treatment of MCD. This is the first report on tocilizumab efficacy for Castleman's disease after approval for use for Castleman's disease.

Information related to the author
© 2007 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top